Navigation Links
Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates
Date:1/9/2012

e peptide-1 (GLP-1) market and invest in the BYDUREON opportunity.
  • Secure a partner outside the U.S. for exenatide. While Eli Lilly and Company continues to provide uninterrupted patient supply and support for BYETTA and BYDUREON in markets outside the U.S., Amylin is committed to ensuring a seamless transition of exenatide responsibilities in those markets to one or more new partners to maximize the global potential of these innovative products and future exenatide products.
  • Maximize the value of BYETTA and SYMLIN. BYETTA is now the only short-acting GLP-1 agonist approved for use as an add-on therapy to insulin glargine in patients with type 2 diabetes, with or without metformin and/or a thiazolidinedione (TZD). For patients not at goal on insulin glargine, adding BYETTA can deliver a complementary approach to glycemic control. Amylin will support SYMLIN with a dedicated commercial organization in 2012. SYMLIN is indicated for patients with type 1 or type 2 diabetes using mealtime insulin and enables patients to achieve more time in the normal glycemic range.
  • Advance the metreleptin development program. In the first half of 2012, Amylin plans to complete the rolling Biologics License Application (BLA) submission for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy, an ultra orphan indication with a dramatic unmet medical need. This program fits with the Company's overall diabetes strategy and can leverage existing commercial infrastructure.
  • Advance exenatide once-weekly suspension and once-monthly suspension global development programs. Amylin plans to begin a Phase 3 program in mid 2012 for exenatide once-weekly suspension. The exenatide suspension formulations do not require reconstitution.
  • Continue focused financial discipline. Building on its record of solid fiscal discipline, Amylin will focus on creation of sha
    '/>"/>

  • SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
    2. Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
    3. Amylin Pharmaceuticals to Present at the Credit Suisse 2011 Healthcare Conference
    4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    5. Amylin Pharmaceuticals to Webcast Third Quarter Results
    6. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    7. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
    8. Amylin Pharmaceuticals to Webcast Second Quarter Results
    9. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
    10. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
    11. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
    (Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
    Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
    ... Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that ... for cardiac biomarker testing on the cobas ® ... labs with medium testing volumes. With a 9-minute duration, ... tests currently available on an integrated platform and enable ...
    ... and MYSTIC, Conn., Sept. 16 Amarin Corporation plc (Nasdaq: ... Financial Officer, is scheduled to present on Amarin,s behalf at ... 2010 at 12:30 pm. This conference will be held at ... Stewart, recently appointed as President and Chief Executive Officer, will ...
    Cached Medicine Technology:Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 2Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 3Amarin to Present at UBS Life Sciences Conference 2
    (Date:8/29/2014)... As reported by WKMS.com in the article ... municipal court drug has come up with a new strategy ... as the presiding judge in a Southeastern Ohio municipal court ... a medicated treatment option that can literally prevent them from ... Vivitrol, which blocks receptors in the brain that would normally ...
    (Date:8/29/2014)... by the Frederick News Post in the article Run For ... the Frederick County Drug Treatment Court has found a new way ... graduate, Korey Shorb, put together a race called Run For Recovery ... donate the proceeds of the event to the program he graduated ... graduated in 2008, admitted that he would probably be in jail ...
    (Date:8/29/2014)... Healthpointe is proud to welcome to ... will be practicing out of Healthpointe’s newest office directly ... Healthpointe’s orthopedic team, Dr. Rodas is board-certified ... in occupational medicine. , Among Dr. Rodas’ many ... of Raytheon, the world-class defense and aerospace company. Additionally, ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 Pursuing its ... is set to unveil a stunning new design that ... company figures, the highly notable surrogacy platform has witnessed ... With over 13,000 visitors a month, the FindSurrogateMother.com community ... working toward one common goal — the precious gift ...
    Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3
    ... Executive says that almost 25 percent of cancer patients in ... the targeted time of two months. //The current data is ... ,The report said that just about 75 percent of all ... fell to 60 percent for bowel cancer patients and those ...
    ... Gripp and his team from DuPont Hospital studied genetic ... scientists found that the gene mutation occured in germline ... of the parents of the affected patients. The researchers ... Interscience. The researchers identified mutations in codon 12 or ...
    ... can be triggered by exposure to endotoxins in the ... Critical Care Medicine study. Humidifiers, pests, dust, pets, and ... according to the University of Iowa’s Dr. Peter S. ... homes selected to represent the demographic characteristics of the ...
    ... Centre International de Recherches Médicales de Franceville has identified ... of infection by the deadly Ebola virus // . ... are eaten in Central Africa by local Congolese and ... the infection is contracted through the eating habits of ...
    ... hope regarding the DNA vaccine trials conducted against the ... have already been completed among 40 HIV- negative // ... in the area of vaccine biology. It involves direct ... antigens into the human body. These vaccines precipitate an ...
    ... women who have had vaginal deliveries prior to their menopause ... their sisters who have never given birth // . In ... to their counterparts. ,Over 10 million people worldwide ... the other. It is a major health issue that ...
    Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2Health News:Urinary Stress Incontinence Not Related To Childbirth 2
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    ... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
    ... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    Medicine Products: